Targeting the D Series Resolvin Receptor System for the Treatment of Osteoarthritis Pain
Open Access
- 16 November 2016
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 69 (5) , 996-1008
Abstract
Objective: Pain is a major symptom of osteoarthritis (OA); currently available analgesics either do not provide adequate pain relief or are associated with serious side effects. The aim of this study was to investigate the therapeutic potential of targeting the resolvin receptor system to modify OA pain and pathology.Methods: Gene expression of 2 resolvin receptors (ALX and ChemR23) was quantified in synovium and medial tibial plateau specimens obtained from patients with OA at the time of joint replacement surgery. Two models of OA joint pain were used for the mechanistic studies. Gene expression in the joint and central nervous system was quantified. The effects of exogenous administration of the D series resolvin precursor 17(R)‐hydroxy‐docosahexaenoic acid (17[R]‐HDoHE) on pain behavior, joint pathology, spinal microglia, and astroglyosis were quantified. Plasma levels of relevant lipids, resolvin D2, 17(R)‐HDoHE, and arachidonic acid, were determined in rats, using liquid chromatography tandem mass spectrometry.Results: There was a positive correlation between resolvin receptor and interleukin‐6 (IL‐6) expression in human OA synovial and medial tibial plateau tissue. In rats, synovial expression of ALX was positively correlated with expression of IL‐1β, tumor necrosis factor, and cyclooxygenase 2. Treatment with 17(R)‐HDoHE reversed established pain behavior (but not joint pathology) in 2 models of OA pain. This was associated with a significant elevation in the plasma levels of resolvin D2 and a significant reduction in astrogliosis in the spinal cord in the monosodium iodoacetate–induced OA rat model.Conclusion: Our preclinical data demonstrate the robust analgesic effects of activation of the D series resolvin pathways in 2 different animal models of OA. Our data support a predominant central mechanism of action in clinically relevant models of OA pain.Keywords
Funding Information
- Arthritis Research UK (18769)
This publication has 49 references indexed in Scilit:
- Differences in structural and pain phenotypes in the sodium monoiodoacetate and meniscal transection models of osteoarthritisOsteoarthritis and Cartilage, 2013
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Resolvin E1 Inhibits Neuropathic Pain and Spinal Cord Microglial Activation Following Peripheral Nerve InjuryJournal of Neuroimmune Pharmacology, 2012
- Infection regulates pro-resolving mediators that lower antibiotic requirementsNature, 2012
- Emerging roles of resolvins in the resolution of inflammation and painTrends in Neurosciences, 2011
- Resolvins and Protectins in Inflammation ResolutionChemical Reviews, 2011
- Targeting Astrocyte Signaling for Chronic PainNeurotherapeutics, 2010
- Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actionsNature Medicine, 2010
- Resolvin D1 binds human phagocytes with evidence for proresolving receptorsProceedings of the National Academy of Sciences, 2010
- An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorptionBritish Journal of Pharmacology, 2008